Baillie Gifford & Co. Sells 119,775 Shares of Codexis, Inc. (NASDAQ:CDXS)

Baillie Gifford & Co. trimmed its holdings in shares of Codexis, Inc. (NASDAQ:CDXS) by 6.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,694,025 shares of the biotechnology company’s stock after selling 119,775 shares during the quarter. Baillie Gifford & Co. owned about 2.08% of Codexis worth $8,080,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in CDXS. Kingswood Wealth Advisors LLC purchased a new position in shares of Codexis during the fourth quarter worth about $79,000. China Universal Asset Management Co. Ltd. bought a new stake in Codexis during the fourth quarter valued at approximately $82,000. Intech Investment Management LLC purchased a new position in Codexis in the 3rd quarter worth approximately $66,000. Jackson Square Capital LLC bought a new position in shares of Codexis in the 4th quarter worth $210,000. Finally, Inspire Investing LLC purchased a new stake in shares of Codexis during the 4th quarter valued at $405,000. 78.54% of the stock is currently owned by institutional investors.

Codexis Trading Up 5.1 %

Shares of CDXS opened at $4.31 on Tuesday. Codexis, Inc. has a fifty-two week low of $2.56 and a fifty-two week high of $6.08. The firm has a market cap of $350.75 million, a price-to-earnings ratio of -4.95 and a beta of 2.12. The firm has a 50 day moving average price of $4.82 and a 200-day moving average price of $3.90. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.15 and a current ratio of 3.21.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on CDXS. Cantor Fitzgerald reiterated an “overweight” rating and issued a $11.00 target price on shares of Codexis in a research report on Friday, November 22nd. Benchmark reaffirmed a “hold” rating on shares of Codexis in a research note on Monday, November 4th.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.